BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2679083)

  • 1. Efficacy and tolerability of simvastatin (MK-733).
    Stalenhoef AF; Mol MJ; Stuyt PM
    Am J Med; 1989 Oct; 87(4A):39S-43S. PubMed ID: 2679083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I.
    Stein E; Kreisberg R; Miller V; Mantell G; Washington L; Shapiro DR
    Arch Intern Med; 1990 Feb; 150(2):341-5. PubMed ID: 2405804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [HMG-CoA reductase inhibitors in familial hypercholesterolemia. Therapy with simvastatin alone and in combination with cholestyramine in low dosage; a report of 2 years experiences].
    Geisel J; Oette K; Burrichter H
    Fortschr Med; 1990 Feb; 108(4):71-2, 75-6. PubMed ID: 2312032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia.
    Mol MJ; Erkelens DW; Gevers Leuven JA; Schouten JA; Stalenhoef AF
    Atherosclerosis; 1988 Feb; 69(2-3):131-7. PubMed ID: 3279966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simvastatin (MK 733) in heterozygous familial hypercholesterolemia: a two-year trial.
    Leclercq V; Harvengt C
    Int J Clin Pharmacol Ther Toxicol; 1989 Feb; 27(2):76-81. PubMed ID: 2921098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with simvastatin compared with cholestyramine.
    Erkelens DW; Baggen MG; Van Doormaal JJ; Kettner M; Koningsberger JC; Mol MJ
    Drugs; 1988; 36 Suppl 3():87-92. PubMed ID: 3254824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of simvastatin on plasma lipids, lipoproteins and apoproteins (A1 and B). 24 cases of major primary hypercholesterolemia].
    Aubert I; Emmerich J; Charpak Y; Chanu B; Dachet C; Herlich D; Besseau M; Rouffy J; Jacotot B
    Presse Med; 1988 May; 17(18):901-4. PubMed ID: 2968595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin (MK 733): an effective treatment for hypercholesterolemia.
    Lintott CJ; Scott RS; Nye ER; Robertson MC; Sutherland WH
    Aust N Z J Med; 1989 Aug; 19(4):317-20. PubMed ID: 2675812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of simvastatin (alone or in association with cholestyramine). A 1-year study in 66 patients with type II hyperlipoproteinaemia.
    Emmerich J; Aubert I; Bauduceau B; Dachet C; Chanu B; Erlich D; Gautier D; Jacotot B; Rouffy J
    Eur Heart J; 1990 Feb; 11(2):149-55. PubMed ID: 2178931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of the addition of fenofibrate to the simvastatin-cholestyramine combination].
    Schlienger JL
    Presse Med; 1991 Mar; 20(12):565. PubMed ID: 1827899
    [No Abstract]   [Full Text] [Related]  

  • 11. Simvastatin and cholestyramine in the long-term treatment of hypercholesterolaemia.
    Ytre-Arne K; Nordøy A
    J Intern Med; 1989 Nov; 226(5):285-90. PubMed ID: 2681508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial.
    Pflugfelder PW; Huff M; Oskalns R; Rudas L; Kostuk WJ
    J Heart Lung Transplant; 1995; 14(4):613-22. PubMed ID: 7578166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome.
    Rabelink AJ; Hené RJ; Erkelens DW; Joles JA; Koomans HA
    Lancet; 1988 Dec; 2(8624):1335-8. PubMed ID: 2904053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of tolerance, efficacy and safety of 3-year simvastatin use in the treatment of primary hypercholesterolemia].
    Darioli R; Bovet P; Brunner HR; Bercher L
    Schweiz Med Wochenschr; 1990 Jan; 120(4):85-91. PubMed ID: 2305221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.
    Steinmetz A; Schwartz T; Hehnke U; Kaffarnik H
    J Cardiovasc Pharmacol; 1996 Apr; 27(4):563-70. PubMed ID: 8847874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
    Bruckert E; De Gennes JL; Malbecq W; Baigts F
    Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia.
    Wierzbicki AS; Lumb PJ; Cheung J; Crook MA
    QJM; 1997 Oct; 90(10):631-4. PubMed ID: 9415344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine.
    Mabuchi H; Sakai T; Sakai Y; Yoshimura A; Watanabe A; Wakasugi T; Koizumi J; Takeda R
    N Engl J Med; 1983 Mar; 308(11):609-13. PubMed ID: 6828091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and safety of simvastatin, a new cholesterol-lowering drug].
    Mol MJ; Stuyt PM; Stalenhoef AF
    Ned Tijdschr Geneeskd; 1989 Feb; 133(7):362-6. PubMed ID: 2927555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia.
    Mol MJ; Stuyt PM; Demacker PN; Stalenhoef AF
    Neth J Med; 1990 Apr; 36(3-4):182-90. PubMed ID: 2355995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.